Safety & interactions
Short sponsored trials report acceptable tolerability, but long-term safety and clinical-outcome evidence are limited. Product claims should disclose the industry-funded evidence base.
Urolithin A supplies a nutrient or bioactive compound intended to alter a defined physiological pathway. The relevant form, baseline status and product quality determine whether the proposed mechanism is clinically meaningful.
Purpose, evidence and practical considerations.
Short sponsored trials report acceptable tolerability, but long-term safety and clinical-outcome evidence are limited. Product claims should disclose the industry-funded evidence base.
Regulatory status: dietary supplement (US); proposed novel-food ingredient (EU/UK, not authorised as of this review — see section 7). Not a medication. Not a device
How people use it, with their schedules, context and original sources.
500–1000 mg
improves mitophagy; human trials show increased strength
Amount and timing patterns reported in public protocols; these are observations, not instructions. Private and hidden usage is excluded.
Brand variants reported in public protocols. Private entries are excluded, and inclusion is not an endorsement.
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.